COMPARING SURVIVAL EXTRAPOLATION OUTCOMES USING DIFFERENT NETWORK META-ANALYSES (NMA) METHODS: AN APPLICATION IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) TREATED WITH IMMUNOTHERAPY (IO) BASED COMBINATIONS

被引：0
|
作者：
Krol, F. [1 ]
Depalma, S. [1 ]
El Alili, H. [1 ]
Verhoek, A. [1 ]
van Beekhuizen, S. [1 ]
Heeg, B. [1 ]
机构：
[1] Cytel Inc, Rotterdam, ZH, Netherlands
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
MSR50
引用
收藏
页码：S359 / S359
页数：1
相关论文
共 50 条
  • [1] Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study
    Saliby, R. M.
    Xie, W.
    Wells, J. C.
    Saad, E.
    Eid, M.
    Semaan, K.
    Labaki, C.
    Ferrier, E.
    Zarba, M.
    Ebrahimi, H.
    Suarez Rodriguez, C.
    Ruiz, J. M.
    Powles, T. B.
    Wood, L. A.
    De Velasco Oria, G. A.
    Takemura, K.
    Braun, D. A.
    Heng, D. Y. C.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2024, 35 : S1021 - S1022
  • [2] Optimization of immunotherapy-based combinations for metastatic renal cell carcinoma: A network meta-analysis
    Park, Sohyeon
    Park, Kalynn
    Kim, Chaeyoon
    Rhie, Sandy Jeong
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2025, 208
  • [3] SYNTHESIZING EVIDENCE ON OVERALL SURVIVAL AND ASSESSING THE FEASIBILITY OF NETWORK META-ANALYSES FOR PREVIOUSLY UNTREATED ADVANCED/METASTATIC RENAL CELL CARCINOMA THERAPIES
    Grevinga, M.
    Szabo, N.
    Ejzykowicz, F.
    Chun, D. S.
    Kurt, M.
    Malcolm, B.
    May, J.
    Kroep, S.
    VALUE IN HEALTH, 2020, 23 : S750 - S750
  • [4] First-line immunotherapy-based combinations for metastatic renal cell carcinoma: Systematic review and network meta-analysis
    Quhal, F.
    Mori, K.
    Mostafaei, H.
    Laukhtina, E.
    Pradere, B.
    Shariat, S. F.
    Schmidinger, M.
    EUROPEAN UROLOGY, 2022, 81 : S593 - S594
  • [5] First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
    Quhal, Fahad
    Mori, Keiichiro
    Bruchbacher, Andreas
    Resch, Irene
    Mostafaei, Hadi
    Pradere, Benjamin
    Schuettfort, Victor M.
    Laukhtina, Ekaterina
    Egawa, Shin
    Fajkovic, Harun
    Remzi, Mesut
    Shariat, Shahrokh F.
    Schmidinger, Manuela
    EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (05): : 755 - 765
  • [6] FIRST-LINE IMMUNOTHERAPY-BASED COMBINATIONS FOR METASTATIC RENAL CELL CARCINOMA: SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
    Quhal, Fahad
    Mori, Keiichiro
    Laukhtina, Ekaterina
    Pradere, Benjamin
    Mostafaei, Hadi
    Shariat, Shahrokh F.
    Schmidinger, Manuela
    JOURNAL OF UROLOGY, 2022, 207 (05): : E176 - E176
  • [7] CRP: A BIOMARKER OF SURVIVAL IN METASTATIC RENAL CELL CARCINOMA PATIENTS TREATED WITH SUBCUTANEOUS IL-2-BASED IMMUNOTHERAPY
    Guida, M.
    Casamassima, A.
    Picciariello, M.
    Berardino, R.
    Ranieri, C.
    Montenegro, E.
    Quaranta, M.
    Lorusso, V.
    ANNALS OF ONCOLOGY, 2004, 15 : 40 - 40
  • [8] 46 Radiological tumor burden is an independent risk factor for survival in patients with metastatic clear cell renal cell carcinoma (mccRCC) treated with first line immunotherapy (IO)-based regimens
    Nawfal, Rashad
    Eid, Marc
    Semaan, Karl
    Paul, Morgan A.
    Saliby, Renee Maria
    Chehade, Razane El Hajj
    Machaalani, Marc
    Phillips, Noa
    Canniff, John
    Saad, Eddy
    Vasseur, Damien
    Zarif, Talal El
    Yekeduz, Emre
    Sun, Maxine
    Baca, Sylvan C.
    Braun, David
    Xie, Wanling
    Krajewski, Katherine
    Choueiri, Toni
    ONCOLOGIST, 2024, 29 : S25 - S26
  • [9] Association of modified Glasgow Prognostic Score (mGPS) with survival outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (CPI)
    Brown, Jacqueline T.
    Liu, Yuan
    Martini, Dylan J.
    Shabto, Julie M.
    Hitron, Elise
    Russler, Greta
    Caulfield, Sarah
    Yantorni, Lauren Beth
    Joshi, Shreyas S.
    Kissick, Haydn
    Ogan, Kenneth
    Carthon, Bradley Curtis
    Kucuk, Omer
    Harris, Wayne
    Master, Viraj A.
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [10] Survival benefit of nephrectomy prior to immunotherapy-based combinations in patients with metastatic renal cell carcinoma: An FDA pooled analysis.
    Fallah, Jaleh
    Gittleman, Haley
    Weinstock, Chana
    Bloomquist, Erik
    Chang, Elaine
    Suzman, Daniel L.
    Agrawal, Sundeep
    Ibrahim, Amna
    Tang, Shenghui
    Pazdur, Richard
    Beaver, Julia A.
    Amiri-Kordestani, Laleh
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345